Podcasts Health JAMA Editors' Summary Sublingual Dexmedetomidine for Agitation in Bipolar Disorder, SARS-CoV-2 Infection and Maternal Morbidity and Mortality, Neurological Outcome in Refractory Out-of-Hospital Cardiac Arrest, and more

Sublingual Dexmedetomidine for Agitation in Bipolar Disorder, SARS-CoV-2 Infection and Maternal Morbidity and Mortality, Neurological Outcome in Refractory Out-of-Hospital Cardiac Arrest, and more

Published: Feb. 22, 2022, 4 p.m.

Editor's Summary by Kristin Walter, MD, Associate Editor of JAMA, the Journal of the American Medical Association, for the February 22, 2022 issue.